Half Year 2026 Basilea Pharmaceutica AG, Allschwil Earnings Call Transcript
Key Points
- Total revenue grew 14% year-on-year to CHF119 million, with operating profit up 32% to CHF32 million.
- Net cash position doubled to CHF105 million, supported by USD61 million in non-dilutive funding from BARDA and CARB-X.
- Cresemba in-market sales reached nearly USD800 million, growing 27% year-on-year, driving strong royalty growth.
- Fosmanogepix Phase 3 program is on track, with nearly 600 patients treated in expanded access and potential to become third commercial product by 2029.
- Zevtera launch is progressing well with improved market access, formulary wins, and expanded field force, supported by US exclusivity until 2034.
- Operating expenses increased due to higher R&D costs for Phase 3 programs and Phase 1 study of BAL2420.
- Product sales guidance was reduced due to partners like Pfizer and Gosun shifting to in-house production, though partially offset by other partners.
- Zevtera revenue contribution is expected to be minimal in the near term, with material impact not anticipated until 2028-2029.
- Fosmanogepix Phase 3 studies may be impacted by localized outbreaks, which could limit enrollment benefits.
- Ceftibuten-ledaborbactam Phase 3 program is still in regulatory discussions, with study initiation not expected until mid-2027.
Ladies and gentlemen, welcome to the Basilea Pharmaceutica half-year results 2026 conference call and live webcast. I am Mathilde, the Chorus Call Operator. (Operator Instructions)
At this time, it's my pleasure to hand over to David Veitch, Chief Executive Officer. Please go ahead.
Thank you. Hello, I'm David Veitch, CEO of Basilea. Thank you for joining us today on our conference call and webcast. We'll be reviewing our financial results and key achievements for the first half-year 2026, as well as highlighting our priorities going forwards.
For further detailed information, please see the ad hoc announcement issued this morning and our half-year report. These documents together with the webcast presentation are all available on our website at basilea.com. I would like to mention that this call contains forward-looking statements.
Joining me on our call today are Adesh Kaul, our Chief Financial Officer; and Dr. Marc
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
